Alkermes plc. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
Alkermes plc. (ALKS) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $11.59 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Notes
us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2021-02-11
- Alkermes plc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2020 was $11.59M, a 49.53% decline from fiscal 2019.
- Alkermes plc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2019 was $22.97M, a 50.39% decline from fiscal 2018.
- Alkermes plc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2018 was $46.30M, a 49.64% increase from fiscal 2017.
- Alkermes plc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2017 was $30.94M.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month |
|---|---|
| 2020-12-31 | $11.59M 10-K · filed 2021-02-11 |
| 2019-12-31 | $22.97M 10-K · filed 2021-02-11 |
| 2018-12-31 | $46.30M 10-K · filed 2021-02-11 |
| 2017-12-31 | $30.94M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |